The Best Operating Quarter of the Coverage, and Management Capped 2027 Before Anyone Could Model It

Results vs. Consensus

Q3 2026 Scorecard

Single-source marks: the Adjusted EBITDA ($3.74B) and GAAP EPS ($6.79) consensus figures each rest on one provider, as do the FY2026 ($29.46) and FY2027 ($32.14) EPS marks.

Two notes on reading this table. First, consensus providers disagreed more than usual on this print: the adjusted EPS mark ranged from $6.65 to $6.74 across three providers and the revenue mark from $19.28B to $19.40B across four. We use the most widely cited figures and the beat is comfortable on any of them. Second, several outlets described the guidance update as a raise, with language such as "raised fiscal 2026 earnings guidance to $29.60 to $30.50 per share from $28.70 to $30.50." That is not what the 8-K says. The formal guidance table is identical to the one issued on July 14. What moved is the company's stated expectation within an unchanged range, to the upper half. The distinction matters for the January comparison.

Year-Over-Year Comparison

Read the cost lines first, because this is the half of the quarter that worked. Salaries and benefits improved 40 basis points as a share of revenue and supplies improved 30, both on revenue growing only 3.6%. That is operating leverage earned on volume rather than price. The entire deterioration sits in other operating expenses, up 120 basis points, and management named the two drivers: provider-tax and related costs that accompany the Medicaid supplemental programs, and professional fees, which it put at roughly 24% of the line and growing 12% year over year.

Below the operating lines, two structural items now cost about 30 basis points of margin a year between them. Depreciation is growing 7.3% on a capital program running at $1.357B a quarter, and interest is growing 8.2% on debt that is $4.0B higher than at December 31. Neither reverses. Both are the price of the volume growth and the buyback respectively, and together they are why income before income taxes fell 2.0% on revenue up 3.6%.

Quarter-Over-Quarter Comparison

The change column above compares Q3 2026 with the comparable-basis Q2 column: the Florida-adjusted figure where the adjustment applies, and the reported figure where it does not, so the cash flow, repurchase and volume rows compare against Q2 as reported. The ~$6.15 clean Q2 EPS ignores any noncontrolling-interest allocation on the Florida catch-up, so the +18.2% is an upper bound.

The sequential column is the most important thing in this report and it needs the Florida adjustment to be visible at all. Q2 included $1.372B of revenue and $829M of matching expense from the Florida directed payment program, of which approximately $980M of revenue and $557M of expense related to periods before 2026. Stripping only that prior-period portion, Q2 Adjusted EBITDA was $3.604B. Q3 printed $3.918B. On reported figures the quarter looks like a 2.7% sequential decline; on comparable figures it is an 8.7% sequential increase, and the Adjusted EBITDA margin expanded roughly 100 basis points rather than contracting 20.

Put the three quarters of 2026 in a row on that basis: Q1 $3.802B, clean Q2 $3.604B, Q3 $3.918B. The trough was the second quarter, which is exactly where the payer-mix shock landed hardest, and the business has grown through it without the headwind going away. We wrote in July that clean sequential Adjusted EBITDA falling below Q1 was "the cleanest single indictment of the quarter's underlying trajectory." The same measure is now the cleanest single piece of evidence that the trajectory turned.

Nine Months Ended September 30

Assessment: Nine months in, income before income taxes is flat and net income attributable is down 0.2% on revenue up 5.5%, and reported EPS is up 9.0% entirely because there are 8.4% fewer shares. That is the 2026 that was forecast in January as a flat-net-income year and then described in July as slightly worse than flat. It is arriving almost exactly as described, and the three quarters contain roughly $650M of incremental Medicaid supplemental net benefit, much of it for services delivered in earlier years. The underlying 2026 is weaker than the reported 2026, and the gap is the thing 2027 has to lap.

Volume, Pricing and Payer Mix

HCA reports as a single operating business, so the equivalent of segment analysis here is payer class, service line and site of care. All three moved this quarter, and not in the same direction.

Operating Statistics

Assessment: This is the cleanest rate column of the coverage. There is no Florida inflation in it, and the filing carries no footnote qualifying the revenue-per-unit lines as it did in July. Same-facility revenue per equivalent admission of +0.6% is low in absolute terms, but it is positive while the uninsured share of volume rose 200 basis points, which means insured pricing is doing real work underneath. Occupancy at 73.2%, up 150 basis points, with length of stay improving another 0.042 days and beds in service essentially flat, is the throughput story management has been describing for two years finally showing up in a single table: more patients through the same physical plant.

The composition is the problem and it has not changed. Admissions and emergency room visits, the lowest-contribution doors, are accelerating. Both surgical categories, the highest-contribution doors, are declining, and outpatient surgery got worse sequentially, from (3.4%) in Q2 to (3.7%) here. The freestanding surgery center count is down six year over year even as the company adds ambulatory sites of care overall, which is the portfolio quietly reshaping around where the volume actually is.

Payer Mix (same-facility equivalent admissions, YoY)

Assessment: Every insured category except exchanges is growing at or above the long-term algorithm, and commercial excluding exchanges accelerated for a second consecutive quarter to 2.7%, which the CFO specifically named as the reason insured rate improved. The exchange line is the whole problem and the whole argument. It missed management's own three-month-old estimate by three to four points while improving sequentially. Those two facts coexist because the comparison base changed: Q3 2025 was HCA's high-water mark for exchange volume, so the same absolute level of exchange business produces a worse year-over-year print this quarter than last.

Surgical Volume by Site of Care

Assessment: The ambulatory platform is taking the worst of it, down 5.4%, which is the opposite of what the network strategy predicts and the opposite of where the capital is going. Management was careful to note that ambulatory net revenue and earnings still grew year over year despite the volume decline, which is a pricing and mix answer rather than a volume answer. The newly named second driver on the inpatient side, the three-year phase-out of the Medicare inpatient-only list starting with orthopaedics and musculoskeletal procedures, is structural and permanent. It does not lap. It is the first element of the elective weakness that cannot be fixed by restoring coverage.

Key Topics & Management Commentary

Overall Management Tone: Confident on the quarter to the point of enumerating wins, and deliberately unhelpful on 2027 beyond a single bottom-line statement. Management volunteered a preliminary 2027 frame it was not required to give, then declined to size any of its three largest moving parts when asked directly four separate times, which is an unusual combination of disclosure and withholding in the same call. The posture on operations was the most assured of the coverage and the posture on the year ahead was the most guarded.

1. The 2027 Frame, and the Word It Leaves Undefined

The CEO put a preliminary 2027 view into prepared remarks three months before guidance is due, built from four components: 2% to 3% volume growth, fewer exchange coverage losses than 2026 but still a meaningful payer-mix effect, $550M to $650M less in Medicaid supplemental net benefits, and favorable cost performance from resiliency and operating leverage.

"When we aggregate these preliminary observations, we anticipate our earnings in 2027 will be generally consistent with 2026. Beyond 2027, we anticipate performance more in line with our long term growth targets." — Samuel N. Hazen, CEO

"Earnings" is doing a great deal of work in that sentence and was never defined. The first question of the Q&A restated it as EBITDA and management did not correct the restatement. The difference is not cosmetic. Flat Adjusted EBITDA of roughly $15.9B, carried through the depreciation and interest growth already visible in this quarter and a share count that keeps falling, produces 2027 EPS somewhere between $28 and $31 depending almost entirely on how many shares get retired. Flat EPS of roughly $30 requires Adjusted EBITDA within about 1% of flat at a 210 million share count, and more than flat if the buyback slows. The two readings overlap in the middle and diverge at the edges by about two dollars of earnings power.

Assessment: Volunteering a 2027 anchor without sizing its components is a choice to control the narrative rather than inform the model, and it worked in reverse. Consensus was at $32.14. A statement that lands 5% to 8% below that, with no components attached and no definition of the term, gives the market nothing to argue with and no reason to hold. The stock fell on one sentence of a call whose numbers were otherwise the best of the year.

2. The Supplemental Cliff Is Now Quantified, and It Is the Bill for 2026

The $550M to $650M reduction in 2027 Medicaid supplemental net benefits is the single hardest number management gave about next year, and its composition was confirmed in Q&A: it is the non-recurrence of grandfathered approvals received during 2026 that paid HCA for services delivered in prior years.

"we expect to receive approximately 550 to 650 million less in Medicaid state supplemental payment net benefit. in 2027 versus 2026. And that is because the grandfather approvals that happened in 2026 that were really related to prior years. ... the rest is really related to the other grandfather states like Virginia, Georgia, etcetera." — Michael A. Marks, CFO

This is precisely the mechanism we flagged in July, now with a price on it. The Florida approval delivered $543M in Q2, of which $423M related to periods before 2026, worth roughly $1.47 per share after tax. We wrote then that the benefit inflates 2026 and burdens 2027. Management has now put the burden at $550M to $650M of Adjusted EBITDA, which is 3.5% to 4.1% of the 2026 base. Holding earnings flat against that requires core growth of roughly 3.6% to 4.3% before anything is spent on the continuing payer-mix drag.

Assessment: The quantification is a genuine service to the model and it removes the bear point's ambiguity without reducing its size. What it does not remove is the asymmetry: the 2026 benefit arrived as a lump sum the company did not forecast, and the 2027 cost arrives as a known subtraction. Earnings quality that depends on state program timing cuts in the direction of the calendar, not the business.

3. Exchange Attrition Missed for the First Time, and Inflected in the Same Quarter

Volume attrition was the one parameter of the three-variable exchange model that had held. In January management assumed a 15% to 20% decline in exchange equivalent admissions; Q1 and Q2 both delivered 15%, at the favorable end. On the Q2 call management guided Q3 to 15% to 16%. Q3 came in at about 19%.

"our HICS results in third quarter were a little bit higher than we estimated. You know, we would have estimated a third based on our guidance that we gave at the second quarter. The third quarter would be 15% to 16% decline. Ended up at about 19% decline, which you know, just reflects the sustained decline in the same. In our exchange volumes. I would like to put that in context, though. I mean, you know, that is that 2 or 3 points is about 2,000 adjusted admissions, you know, just we have about a million adjusted admissions in the quarter." — Michael A. Marks, CFO

Two things are true at once and the call did not reconcile them. The year-over-year decline worsened by three to four points against management's own estimate. And exchange volume improved roughly 8% sequentially from Q2 to Q3, because Q3 2025 was the high-water mark for exchange business and therefore the hardest comparison of the year. The level is stabilising while the growth rate deteriorates, which is what the end of a decline looks like from the inside.

Assessment: All three parameters of the January exchange model have now missed at least once, which retires the model as a forecasting tool. What replaces it is a level observation rather than a rate assumption: the exchange book is now small, the uninsured share has reset 200 basis points higher, and the sequential direction turned up. That is a better footing for 2027 than any of the behavioral assumptions were, and it is also the reason management's "fewer people will lose coverage in 2027" claim is plausible without being verifiable. The scale framing in the answer deserves one note of scepticism: 2,000 adjusted admissions sounds trivial against a million, and the $400M quarterly mix cost says the per-unit economics of a coverage loss are not trivial at all.

4. Uninsured at 10.5% of Volume: the $400M Quarterly Toll

The single largest number in the release is not in the income statement. Management estimates that the payer-mix shift from exchange coverage to uninsured cost approximately $400M of income before income taxes in the quarter, against reported income before income taxes of $2.370B.

"Like the second quarter, we continue to see patients who have lost coverage on the exchanges migrate almost 1-for-1 to uninsured. This 1-for-1 migration makes up approximately 80% of our uninsured volume growth. With the remaining 20% primarily related to a decrease in Medicaid conversion. And mostly in Texas. Our uninsured volume in third quarter 26 represented approximately 10.5% of total equivalent admissions versus 8.5% in the prior year quarter." — Michael A. Marks, CFO

The one-for-one migration finding that broke our April upgrade is now in its second quarter of confirmation, and it was independently corroborated the same morning by a second large hospital operator reporting exchange volume down 17% and describing the self-pay increase as "largely sort of a one-for-one swap." The 80/20 split between exchange migration and slower Medicaid conversion is unchanged from Q2, which means the Medicaid conversion issue has stayed scoped rather than spreading.

Assessment: A 200 basis point shift in the uninsured share of roughly 1.06 million same-facility equivalent admissions is on the order of 21,000 incremental uninsured encounters in the quarter. At $400M that is close to $19,000 of lost contribution per unit, which is the clearest statement available of why volume growth and earnings growth have decoupled. The corroboration from a peer matters more than it looks: it moves the finding from "HCA mis-estimated its own book" to "the sector mis-estimated a behavioral response," and the second is the more forecastable of the two.

5. Core Growth of Roughly 10%, and the Bridge That Supports It

Pressed on whether 2027 core Adjusted EBITDA growth of 4% to 6% still holds, the CFO declined to confirm it and instead disclosed the current quarter's figure.

"When I think about core growth in third quarter, we were pleased with core growth in third quarter and call it a 10% core growth increase. I think that reflects good volume growth. It reflected good net revenue per unit improvement in the quarter. And really good cost management as well." — Michael A. Marks, CFO

We can check that claim with the figures management disclosed. Start from Q3 2025 Adjusted EBITDA of $3.870B, subtract the $400M payer-mix cost and add the $50M of incremental supplemental net benefit, and the residual required to reach the reported $3.918B is $398M, or 10.3% of the prior-year base. Management's 10% and our derivation agree to within three-tenths of a point. The bridge closes.

Assessment: This is the most important disclosure of the call and it was given as an aside in answer to a question management otherwise dodged. Core growth of 10% on a business whose long-term algorithm is mid single digit says the operating engine is running well above trend, and it makes the 2027 framing arithmetically coherent rather than merely cautious: roughly 4% core growth funds the supplemental cliff and nothing else, and the continuing payer-mix drag has to be funded out of whatever core growth exceeds that. A company growing core at 10% can absorb both and still be flat. That is the whole 2027 story in one line.

6. Cost: Flat Unit Cost Through a Second Quarter of the Mix Shock

Same-facility cost per equivalent admission excluding Medicaid supplemental programs was essentially flat year over year for a second consecutive quarter, and improved 40 basis points sequentially in the quarter that normally gets worse.

"typically, when we go from second quarter to third quarter, that is the timing of when we do a lot of our merit adjustments in labor. So we typically see, even a 100 basis point increase in our expense per AA overall. And that is 1 of the factors. And so we were actually really pleased when we looked at our expenses per equivalent admissions... they were essentially flat to prior year, but 2, they were down 40 basis points sequentially from second quarter to third quarter..." — Michael A. Marks, CFO

The seasonal point is the one that matters. A 40 basis point sequential improvement in a quarter that normally carries a 100 basis point merit step-up is a 140 basis point swing against the usual pattern, and it is the first Q2-to-Q3 seam in this coverage in which the cost line has moved the right way. Salaries and benefits improved 40 basis points of revenue and supplies 30, both on only 3.6% revenue growth, which means the leverage came from throughput rather than price.

Assessment: Bull pillar one is now confirmed on two consecutive quarters of evidence, the second of them seasonally stacked against it, and the January 2026 worry about seasonal cost-flex failure is fully retired. This is the best-evidenced element of the thesis and it is the reason the 2027 framing is survivable rather than alarming. It is also still insufficient on its own: the resiliency program was sized against a headwind that has since grown to roughly $1.25B, and management has promoted it from an offset to a permanent operating discipline precisely because it can no longer be described as covering the gap.

7. Professional Fees Re-Accelerate to 12%

The one cost line that improved in Q2 went backwards. Same-facility professional fees grew about 12% year over year, against 8.5% in Q2 and the 11% in Q3 2025 that first made this a thesis point, and they now represent roughly 24% of other operating expenses.

"Professional fees, continue to be a pressure point for the company. We were up about 12% versus prior year quarter. And professional fees now represent about 24% of other operating expenses. And I would note that those continue to be driven by radiology and anesthesiology." — Michael A. Marks, CFO

Roughly 24% of a $4.548B line is about $1.09B in the quarter, growing at more than three times the rate of total revenue. The named drivers, radiology and anesthesiology, are the two specialties with the most concentrated staffing-company intermediation and the least substitutability, and they are the same two drivers management named a year ago. Nothing in the cost program described later on the call addresses them specifically.

Assessment: We de-escalated this bear point to Contained in July on one quarter of improvement. That was premature and we are escalating it back. The re-acceleration to 12% is above the level that originally made it a thesis point, the drivers are unchanged, the specialties are structurally hard to source, and there is still no disclosed plan aimed at them. The saving grace is that total unit cost held flat anyway, which means the rest of the cost base is absorbing it. That is a statement about how good the rest of the cost program is, not about this line.

8. Elective Surgery: a Second Driver, and It Does Not Lap

The bear point we added in July got clearer and slightly worse. Management named exchanges as the largest driver of elective surgical weakness, as before, and then added a second.

"if I look at our elective book, I would say, you know, after the changes, which was the biggest driver of elective surgical volume weakness the second driver would have been Medicare, especially on the inpatient side. So we are seeing some impact of the inpatient only list." — Michael A. Marks, CFO

The inpatient-only list is in year one of a three-year phase-out and currently concentrated in orthopaedics and musculoskeletal procedures. Management's own framing of the competitive consequence is candid: the outpatient surgical market is larger than the inpatient one and has more competitors, so procedures migrating out of the hospital land in a less favorable competitive position. On the affordability component, the CEO was asked to separate it from the coverage effect and could not.

"Coverage for people matters, and it creates access affordability, and elective care. it is a very fundamental element to individuals' abilities to get the health care they need And so it is it is a large piece of the elective equation is the coverage dynamic that is occurred in the HICS environment. And I do not have an exact percentage here in front of you, but it is a very significant piece of the variance." — Samuel N. Hazen, CEO

Management also declined to assume any fourth-quarter pull-forward from deductible resets, which it has seen in prior years, and offered the diversification argument as the mitigant: cardiac, neonatal, trauma and emergency medical services volumes are all described as strong and compensating.

Assessment: The attribution problem we flagged in July is partly resolved and the resolution is not good. Of the three candidate causes, one laps (exchange coverage loss), one is structural and permanent (the inpatient-only list), and one is unsized and macro (affordability). Adding a permanent driver to the mix lowers the ceiling on any eventual elective recovery, and the ambulatory platform taking the worst of the decline at (5.4%) is where the capital is going. The diversification answer is true and it is also the answer a company gives when it cannot fix the specific thing.

9. Insured Rate Growth Accelerates: the Offsetting Half

The disclosure that explains most of the beat got the least attention. Insured revenue per equivalent admission excluding exchanges grew faster in Q3 than in the first half, and management named three contributors.

"Number 1 is really the strength of our commercial volume. Our commercial, excluding exchanges volume, was up 2.7% over prior year quarter, and that is strong... The second, we continue to see solid rate growth across our peer of payer categories. And then, really, third, Paralon, we see continued strength in their abilities to collect our net revenues and yield our contracts..." — Michael A. Marks, CFO

The third contributor is the interesting one. Revenue cycle yield, collecting more of what has already been billed under existing contracts, is the first of the four resiliency pillars management described later in the call, and it is the only one that shows up in revenue rather than cost. It is also the pillar most exposed to a growing uninsured book, where collectability is structurally worse.

Assessment: Positive same-facility rate growth of 0.6% while the uninsured share of volume rose 200 basis points implies insured pricing well above that headline, and the commercial book accelerating for a second consecutive quarter is the best possible composition. This is the mechanism by which the payer-mix shock becomes survivable rather than compounding. One caution: a revenue-integrity contribution to rate is a one-time catch-up in each contract it touches, not a recurring growth rate, and nobody asked how much of the acceleration it was.

10. Capital Allocation: Q3 Paid for Itself, and the Authorization Runs Out

The cash concern we raised in July eased substantially in the quarter and remains real for the year. Operating cash flow of $4.461B covered $1.357B of capital expenditure, $2.970B of repurchases and $165M of dividends to within $31M. Accounts receivable fell $772M from June 30 as the Florida receivable converted.

The execution deserves credit. HCA repurchased 7.230 million shares at an average of $410.79, which is $39 below the reaction-day close and $60 below the average price it paid in Q4 2025. Buying the most stock at the lowest price of the year is what a capital allocation pillar is supposed to look like. Against that, the nine-month picture still does not fund itself: capital expenditure, repurchases and dividends total $10.831B against $8.810B of operating cash flow, a $2.0B shortfall, $2.96B with acquisitions included, and total debt is up $4.0B since December 31.

"Our debt to adjusted EBITDA leverage remains in the lower half of our state target range... We currently expect to complete most of the existing authorized share repurchase program by year end. Subject to market conditions and other factors." — Michael A. Marks, CFO

Assessment: Leverage on our derived trailing twelve-month Adjusted EBITDA of $15.861B is about 3.1 times net, which is consistent with management's description and not a constraint. The constraint is the authorization. $4.240B remains, management intends to spend most of it by December 31, and no new authorization has been announced. Every reported EPS growth rate in this coverage has depended on a shrinking share count. The sentence above says the mechanism stops working in roughly ten weeks unless the board acts, and the one question nobody asked on this call was when it will.

11. Guidance: an Expectation Narrowed, Not a Range Raised

The 2026 ranges issued on July 14 are unchanged. What moved is the company's expectation within them, to the upper half, and the CFO gave the three-part bridge when asked.

"yes, I mean, from supplemental payments, we have raised our net benefit guidance by about $300 million. So that is certainly a piece of it. If you think about the big changes with this idea of kind of at or slightly above the top end of our previously released estimates. You know, you are in the $100 million to $200 million increase in headwinds related to that. And then the third thing I would call out is just core growth." — Michael A. Marks, CFO

Assessment: The implied Q4 is undemanding at the midpoint and the operating content behind it is better than the headline. Revenue up 0.9%, Adjusted EBITDA up 1.6% and adjusted EPS up 0.9% against a Q4 2025 that was a strong quarter, with only about $50M of incremental supplemental benefit implied at the midpoint, means the core growth the CFO says continues at roughly 10% is funding the whole thing. One item worth marking: the $100M to $300M H2 supplemental headwind management guided in July has not appeared. Q3 delivered a $50M incremental net benefit and the raised range implies roughly $50M more in Q4. On the two disclosures as given, H2 is a modest benefit rather than the headwind guided three months ago.

12. Policy Options Outside Guidance, Sized and Unsized

Three policy channels were discussed and none is in guidance. The proposed Medicare outpatient prospective payment rule includes a budget-neutral reallocation of 340B, which management expects to benefit HCA and declined to size. HR1 Medicaid work requirements were scoped for the first time with real denominators. And the inpatient-only list phase-out is already in the numbers, as covered above.

"I would mention on HR 1 that, you know, the big change is really work requirements for able-bodied adults. In our expansion states. You know, I might mention just for context that expansion states are 40% of our Medicaid volumes and revenues. When you think about work requirements targeting able-bodied adults in those expansion states, You take out the seniors and the disabled and the kids and those that are medically frail, we think that work requirements would be kind of applicable to about 15% to 20% of our Medicaid-like." — Michael A. Marks, CFO

On 340B the posture was notably warmer. Management said it was "pleased with the construct" of the proposed rule, called it "a positive factor for HCA as we head into 2027," and said it is "hoping that it gets finalized here soon," while declining to quantify. It then added the caveat that matters: the "generally consistent" 2027 statement reflects where things stand at the third quarter, which implies the 340B benefit is not inside it.

That answer contains two denominators and does not say which one the second figure attaches to. Expansion states are 40% of Medicaid volumes and revenues. Work requirements are described as applicable to 15% to 20%, and the sentence can be read either as 15% to 20% of total Medicaid volume or as 15% to 20% of the expansion-state subset. The two readings differ by a factor of two and a half. Management called the 2027 earnings effect "modest" either way and declined to size it, so we carry the wider reading and treat the exposure as bounded rather than measured.

Assessment: This is the first quarter of the coverage in which the policy ledger has a credit on it. Work requirements finally have denominators attached, even if the denominators are ambiguous, and "modest" is the first adjective management has applied to this risk. And a 340B reallocation that management describes as positive and excludes from its preliminary 2027 frame is the first unguided upside channel since the Florida approval, which was worth $543M. Both are options rather than estimates. Neither belongs in a base case, and the second is the single most plausible route to a January guide above "generally consistent."

13. Resiliency: Four Pillars, Still No Dollars

Asked to describe what resiliency has delivered and what is left, the CFO gave the most structured answer of the coverage and no figures: revenue integrity, asset optimization and patient flow, variable cost, and fixed cost at corporate and in the field.

"We are nowhere near the back 9 here on asset optimization and feel good about the work ahead there... as I sit here today, at the end of third quarter of 2026, we believe that we are in a really good spot. We have a multiyear multifaceted enterprise wide approach to resiliency, and we believe it is going to produce great results as we move forward." — Michael A. Marks, CFO

The CEO's framing was the more consequential one. Resiliency has been reclassified from a program with a target to a permanent capability, enabled by new technology and an expanding shared-service platform, that will keep producing value through 2027, 2028 and beyond.

Assessment: The reclassification is credible on two quarters of flat unit cost and it is also convenient. A permanent operating discipline has no completion date and therefore no scoreboard. We have now asked for five consecutive quarters whether there is a cumulative figure against the $600M to $800M target set at the 2023 investor day, and there still is not one. The digital transformation described as the key enabler remains undisclosed as to cost, timeline and disruption risk. The results are visible in the margin; the accountability is not visible anywhere.

Analyst Q&A Highlights

Nineteen analysts were taken under a one-question limit, and the distribution was lopsided: nine of them reached for 2027 in some form. Management answered the mechanical ones precisely and declined every attempt to size a component of next year.

Sizing the 2027 exchange headwind

The first question of the call went straight at the gap in the preliminary 2027 frame: if the exchange headwind is incremental and the resiliency savings are incremental, what are the two numbers? The request explicitly offered to accept a wide range. Management declined to give one, and the reason it gave is the most informative part of the answer: the open enrollment period runs from November 1 into mid-January, so the company will have both fourth-quarter actuals and enrollment intelligence before the January call and not before.

Q: "I wonder if there is any way to flush out sort of a order of magnitude of what you think that incremental public exchange headwind might be next year even if it is a wide range. Similarly so, should we look for cost savings similar to $400 million resiliency program you announced this year or next year?"
— Albert Rice, UBS

A: "as we go through the fourth quarter first, we will have a better information about how our exchange volumes perform here in the last quarter of the year. But we will also have better intelligence about enrollment. The enrollment period starts on November 1 and goes to you know, mid January. And so with those 2 things, you know, we will be in a much better position to give you our best sense of this on our January call."
— Michael A. Marks, CFO

Assessment: A legitimate reason to withhold, and it leaves the single largest 2027 variable unsized for three more months. The timing disclosure is useful on its own: it means the January guide will be built on observed enrollment rather than modeled behavior for the first time since this headwind appeared, which should make it more reliable than any of the three estimates that preceded it. It also means nothing between now and January will resolve it.

Whether the 4% to 6% core growth framework survives into 2027

The most direct attempt to put a number on next year asked management to confirm that core Adjusted EBITDA growth of 4% to 6% still holds, with the policy items layered on top. Management did not confirm it and did not deny it. What it offered instead was the current quarter's core growth figure, roughly 10%, and a pointer to the upper-half guidance comment as the implied read on Q4. That aside is the quarter's most valuable disclosure and it was volunteered in place of the answer.

Q: "You talked qualitatively about mix and Medicaid impact next year. And the core mission growth of 2% to 3%. Can you just confirm that 2027, the adjusted core EBITDA growth is still in the 4% to 6% range? The other piece is impacting that, or is core running hotter or lower. How much is resiliency driving that core growth?"
— Pito Chickering, Deutsche Bank

A: "resiliency is just part of our core operations, and so that is the way we think about resiliency is just part of the work we do every day in managing the company. When I think about core growth in third quarter, we were pleased with core growth in third quarter and call it a 10% core growth increase... And I think if you see how we kind of set the guidance range in the upper half of range, that gives you a sense of how we are thinking about fourth quarter."
— Michael A. Marks, CFO

Assessment: Trading a framework confirmation for a current-quarter datapoint is a good exchange for the analyst and a telling one for the thesis. Management will say core growth is 10% now and will not say what it is next year, which implies the 2027 core number is lower, or that it is not yet known, or both. Folding resiliency into "core operations" also quietly removes the separate line item that was supposed to be tracked against a target. The answer is a dodge and the dodge contained the best number on the call.

Composition of the 2027 Medicaid supplemental step-down

A request to decompose the $550M to $650M between the HR1-driven directed-payment reduction and the non-recurrence of 2026 out-of-period catch-up got a clean answer, and it is the answer that makes the number forecastable. Essentially all of it is the second category, and the predominance of that is Florida. The same question asked for the fourth-quarter sequential exchange assumption and did not get it.

Q: "First on 2027 DSH, appreciate the $550 million to $650 million number. I was hoping you can isolate your estimate here of how much of that number comes from the Q4 DPP cut as HR 1 gets implemented? Versus the 2026 out of period that does not reoccur? Is there any exchange impact for Q4?"
— Justin Lake, Wolfe Research

A: "that is because the grandfather approvals that happened in 2026 that were really related to prior years. The predominance of that, Justin, was related to Florida which we previously disclosed. You know, the rest is really related to the other grandfather states like Virginia, Georgia, etcetera... we are finished September 2026 year to date with $650 million of incremental net from state supplemental payments... at midpoint, it would be another $50 million net. Incremental benefit, and then you can see the range."
— Michael A. Marks, CFO

Assessment: This is the most useful exchange of the call. The supplemental cliff is a timing artifact rather than a policy cut, which means it is knowable to the dollar and does not recur in 2028. It also means the 2026 base is overstated by roughly the same amount, confirming the per-share adjustment we have been carrying since July. The refusal to give a Q3 to Q4 sequential exchange figure, after volunteering the Q2 to Q3 figure unprompted in prepared remarks, is the one place the selective disclosure is visible.

Why exchange attrition came in three to four points worse than guided

A recurring line of questioning pressed on the gap between the 15% to 16% third-quarter exchange decline management guided in July and the roughly 19% delivered. The answer conceded the miss without hedging, attributed it to the Q3 2025 high-water-mark comparison, and paired it with the sequential improvement. The same question also asked about accounts receivable collectability on the growing uninsured book, and that half went unanswered.

Q: "Did the HICS headwind get larger in any particular market? And any comments around AR collectability, balance after collectability would be helpful. And any of the 400 million is that related to prior quarters?"
— Whit Mayo, Leerink

A: "our HICS results in third quarter were a little bit higher than we estimated. You know, we would have estimated... The third quarter would be 15% to 16% decline. Ended up at about 19% decline... We did see, however, a sequential improvement in exchange volume from second quarter to third quarter 26 of about 8%. And so all of that, when we brought it together, you know, it is kind of what guided us to say that we think for full year 2026 now, you know, we will be at to maybe slightly above the top end of our previously updated ranges..."
— Michael A. Marks, CFO

Assessment: Three questions were asked and one and a half were answered. The market-level question got nothing, which is notable given that three of fifteen divisions carried roughly half the impact last quarter, and the collectability question got nothing, which matters more: the uninsured share of volume has risen 200 basis points and nobody learned anything about what is collectable from it. Accounts receivable fell $772M sequentially, but that is the Florida receivable converting and says nothing about the uninsured book.

Separating affordability from coverage in the elective decline

One question tried to split the elective surgical weakness into its coverage and affordability components and to establish whether a fourth-quarter deductible-reset pull-forward is assumed, and a later question returned to the fourth-quarter point. Management declined both, assumed only normal seasonality for Q4, and conceded it does not have the split.

Q: "is there a way to unpack how much of the inpatient and outpatient surgical trend pressure so far this year is exchange related versus how much is affordability and things that may be continuing. And then given your comment on affordability pressure, are you assuming any stronger than normal tailwind in 4Q ahead of the deductible reset?"
— Sarah James, Cantor Fitzgerald

A: "We are not at this particular juncture, anything outside of normal. Seasonality, but your point is relevant It could be that some folks are making decisions. We have seen that on the margin. In other years, but at this particular point in time, we are not... And I do not have an exact percentage here in front of you, but it is a very significant piece of the variance."
— Samuel N. Hazen, CEO

Assessment: The same answer as July, three months and one quarter of further deterioration later. Not assuming a Q4 pull-forward is conservative and removes one source of guidance risk. Still being unable to size the affordability component after two quarters of asking is the live problem, because the two components have opposite implications: coverage loss laps in 2027 and affordability does not. The one new piece of information came from a different question, where management named the Medicare inpatient-only list as the second driver, and that one does not lap either.

The cost lines, and what is inside other operating expenses

A question about the sequential movement in salaries and benefits versus other operating expenses, framed around whether temporary staffing orders are picking up industry-wide, produced the quarter's most complete cost walk. Management did not engage the temporary-staffing premise at all. It gave the merit-timing explanation for the salaries step-up, the seasonality context that makes the 40 basis point sequential improvement impressive, the provider-tax content inside other operating expenses, and then the professional fees disclosure unprompted.

Q: "as I look at the SWB and the operating expense lines, SWB up sequentially other OpEx down. Anything you can call out there, especially as we think through TAP staffing, we are seeing indicators that it looks like temp staff orders are picking up So just curious what you can share with us on those 2 line items, especially given the resiliency efforts."
— Brian Tanquilut, Jefferies

A: "typically, when we go from second quarter to third quarter, that is the timing of when we do a lot of our merit adjustments in labor. So we typically see, even a 100 basis point increase in our expense per AA overall... Professional fees, continue to be a pressure point for the company. We were up about 12% versus prior year quarter. And professional fees now represent about 24% of other operating expenses. And I would note that those continue to be driven by radiology and anesthesiology."
— Michael A. Marks, CFO

Assessment: Volunteering a cost line that re-accelerated to 12% when the question did not ask about it is the behavior of a management team that expects to be checked, and it is consistent with how the exchange miss was handled in July. The unanswered half is the temporary-staffing premise. If contract labor demand is rising across the industry, that is the mechanism by which two quarters of flat unit cost could end, and the company that just beat its own cost seasonality was the right one to ask.

What moved the expectation to the upper half of the range

The clearest piece of guidance mechanics on the call came from an analyst proposing the bridge himself and asking management to confirm it. The confirmation came with the third component added, and it is the one that matters: core growth, unsized for the year but running at roughly 10% in Q3 and described as "fairly consistent" in Q4.

Q: "I just a lot of moving pieces here. So I just wanna make sure I understand the new guidance versus the old guidance. Is the right way to think about that the new guidance includes about $300 million more of STPs and $100-plus million more of headwinds from payer mix and then that combination is largely the increase in guidance from the prior guidance."
— Kevin Fischbeck, Bank of America

A: "yes, I mean, from supplemental payments, we have raised our net benefit guidance by about $300 million. So that is certainly a piece of it... you are in the $100 million to $200 million increase in headwinds related to that. And then the third thing I would call out is just core growth... The net of those 3 factors really led us to making the comment that we believe will be in the upper end of our guidance ranges for the full year."
— Michael A. Marks, CFO

Assessment: The bridge nets to roughly $100M to $200M of favorable policy items plus an unquantified core contribution, against an Adjusted EBITDA range $700M wide. The policy items alone are roughly the size of the move from the range midpoint to the middle of the upper half, so the arithmetic does not by itself show how much core growth contributed, though management named it as the third factor. The low implied Q4 supplemental benefit does mean the fourth quarter is carried by operations rather than by a program approval, and that is checkable in January.

What They're NOT Saying

1. What "earnings" means in the 2027 statement: flat Adjusted EBITDA and flat EPS are roughly two dollars of earnings power apart, the term was never defined, and the first questioner's restatement of it as EBITDA went uncorrected. For a sentence that cost the stock 3.3% on the day, the ambiguity is doing more damage than a number would have.
2. The size of the 2027 exchange headwind: asked directly, with an explicit offer to accept a wide range, and declined. It is the largest single variable in next year, and management put no number against it.
3. Whether 2027 core growth is still 4% to 6%: asked as a yes-or-no confirmation and answered with a Q3 datapoint instead. Declining to reaffirm a framework while disclosing that the current quarter is running at roughly 10% implies the answer is lower.
4. A new share repurchase authorization: $4.240B remains, management expects to complete most of it by year end, and no replacement was announced. Every EPS growth rate in this coverage has been share-count driven. Nobody asked, which is the more surprising half.
5. Any cumulative figure against the resiliency target: the fifth consecutive quarter without one. The program was described in four qualitative pillars and reclassified as a permanent capability, which removes the completion date and with it the scoreboard against the $600M to $800M set at the 2023 investor day.
6. The cost, timeline or disruption risk of the digital transformation: named as the key enabler of resiliency benefits in 2027 and 2028 and still undisclosed in every dimension.
7. The 340B benefit: described as a positive factor for 2027 and explicitly not sized. Management also clarified that the "generally consistent" statement reflects the position as of the third quarter, which places the 340B option outside it.
8. Which denominator the Medicaid work-requirement exposure sits on: management gave 40% of Medicaid volume in expansion states and 15% to 20% applicability in the same answer, without saying whether the second figure is a share of total Medicaid or of the expansion-state subset. The two readings differ by a factor of two and a half on a risk management is willing to call "modest" but not to size.
9. Collectability on the growing uninsured book: asked plainly as part of a multi-part question and skipped. Uninsured volume is 10.5% of equivalent admissions against 8.5% a year ago, and the quarter's $772M sequential receivables decline is Florida converting, not an answer.
10. The Q3 to Q4 sequential exchange assumption: declined, one answer after volunteering the Q2 to Q3 sequential figure unprompted. Management instead pointed to the easier Q4 2025 comparison, which is a comparison point rather than an assumption.
11. The $450M of the July guidance cut that disclosed assumptions never explained: never revisited, and never asked about. The expectation has since moved to the upper half of the same range, which arguably resolves it in the company's favor without anyone confirming what it was.
12. Whether contract labor demand is rising: a question about industry-wide temporary staffing orders picking up was not engaged. That is the most plausible mechanism by which two quarters of flat unit cost could end.

Market Reaction

• Pre-print setup: HCA closed October 26 at $465.26, down 0.3% year to date, down 0.6% over twelve months and up 6.8% over the trailing thirty days. The pre-print 52-week closing range was $361.32 to $545.13, placing the stock 28.8% above the low and 14.7% below the high. The S&P 500 was up 12.1% year to date over the same period, so HCA entered the print roughly twelve points behind the index for the year.
• Pre-market reaction to the release: the shares printed as high as $491.76, up 5.7%, on the 8-K alone, before the 10:00 a.m. ET call.
• October 27 reaction session: opened at $480.00, up 3.2%. Traded to a high of $488.00, up 4.9%, and a low of $439.83, down 5.5%. Closed at $449.96, down 3.3% or $15.30. The S&P 500 rose 0.6% on the day.
• Intraday range and volume: $48.17 from high to low, or 10.4% of the pre-print close, on 2.9 million shares against a 1.3 million 30-day average, 2.3 times normal.
• Peer reaction: a second large publicly traded hospital operator reported the same morning, disclosed exchange volume down 17% and described the migration to self-pay as close to one-for-one, and its shares also fell pre-market. The exchange mechanism is being priced as a sector issue, not a company issue.

A reversal priced on one sentence. The sequence is unusually legible. The release went out before the open and the stock traded up 5.7% on it, which is the market pricing a 2.7% revenue beat, a 7.1% EPS beat, a 4.8% Adjusted EBITDA beat and a guidance expectation moved to the upper half. The call began at 10:00 a.m. ET and the CEO's preliminary 2027 commentary arrived in prepared remarks. By the close the stock had given back the gap and 3.3% more. Nothing in the 8-K changed between the open and the close. The entire 9 percentage point round trip is attributable to a forward statement management was under no obligation to make.

The setup made the stock vulnerable to exactly this. HCA entered the print up 6.8% over thirty days and roughly flat for the year against an index up 12.1%, which is the positioning of a name being accumulated on a recovery thesis rather than owned for momentum. A recovery thesis needs a 2027 that grows. Consensus was carrying $32.14. "Generally consistent with 2026" against an upper-half 2026 of $29.60 to $30.50 is 5% to 8% below that mark, and it was delivered without the component detail that would let a holder argue the number is conservative. Positioning built on 2027 growth cannot survive the company capping 2027 growth, however good the current quarter is.

Why the tape and the sell-side moved in opposite directions. The early sell-side actions raised price targets, several by more than 10%, to levels above both the pre-print close and the reaction close. The resolution is that the two groups were pricing different years. The sell-side marked models to a 2026 whose expectation had just been narrowed upward and whose fourth quarter is undemanding, and applied the multiple it was already using. The tape marked the stock to a 2027 that management had just described as flat, and applied a lower multiple to a lower number. Both are internally consistent. Only one of them is about the year that will be in the price twelve months from now.

Street Perspective

Debate: Did the Street or the Tape Read This Quarter Correctly?

Bull view: The quarter beat on every line with a consensus mark, core growth is running at roughly 10%, unit cost beat its own seasonality, volume hit the top of the long-term range, and the 2027 comment was explicitly labelled preliminary, early in the planning cycle and subject to a policy environment management called fluid. Management has a two-year record of describing next year conservatively and then delivering above the initial frame. Marking the stock down on the most hedged sentence of the call, while the business is visibly accelerating, is a positioning event rather than an analytical one.

Bear view: Companies do not volunteer a bottom-line anchor three months early unless they want expectations reset, and the only hard number inside it, the $550M to $650M supplemental step-down, is a subtraction. The three components management refused to size are all headwinds. Core growth of 10% is being measured against a payer-mix-depressed base, so it flatters the comparison. And a flat 2027 against consensus of $32.14 means the sell-side numbers are wrong by 5% to 8% and have to come down regardless of what the targets say this week.

Our take: The tape read it correctly and the sell-side read the quarter correctly, which is not the same question. A beat against a Q3 mark is worth very little when the company has just told you where the next four quarters land. The bulls are right that the frame is hedged and right that 340B sits outside it, and those are the two routes to a January guide above flat. They are not reasons to pay fifteen times for a flat year today. The honest summary is that this quarter improved our confidence in the business and lowered our estimate of the stock's upside, because management narrowed the distribution of 2027 outcomes and did it from the top.

Debate: Is "Generally Consistent with 2026" a Floor or a Ceiling?

Bull view: It is a floor. The statement excludes the 340B reallocation management expects to benefit from and called a positive factor for 2027. It excludes any narrowing of the exchange headwind that November-to-January enrollment data might produce, and management has already said it expects fewer coverage losses than in 2026. It is built before the fourth quarter validates core growth, which the CFO expects to run at roughly the Q3 rate. And the comparison base itself, the upper half of the 2026 range, is being revised up not down. Every variable inside the statement is one management has described as more likely to improve than deteriorate.

Bear view: It is a ceiling and the components say so. The supplemental cliff is a fixed subtraction of 3.5% to 4.1% of the base. The payer-mix drag continues, described as "meaningful" and unsized. Depreciation is growing 7.3% and interest 8.2% on a balance sheet $4.0B more levered than in December, and both compound into next year. The buyback that supplies all the per-share growth has $4.240B of authorization left and most of it spent by December. A company that will not confirm 4% to 6% core growth for 2027 while disclosing 10% for the current quarter is signalling deceleration, not conservatism.

Our take: It is a ceiling on the reported number and a floor on the operating number, and the difference is the share count. Flat Adjusted EBITDA at roughly $15.9B, carried through the depreciation, interest and minority-interest growth now visible, produces net income attributable near $6.2B to $6.4B, which is down on 2026. Whether that becomes $28 or $31 of EPS is decided by a board authorization, not by the hospitals. That is an uncomfortable place for the central variable of a thesis to sit, and it is why we are modeling the middle of the range rather than either end.

Debate: Is the Elective Decline Affordability or Structural Migration?

Bull view: It is overwhelmingly coverage, which laps. Management has named exchange losses as the largest driver in both quarters since the decline was flagged, the ambulatory surgery decline of 5.4% is attributed to the same cause as the hospital decline, and the compensating services are genuinely strong: cardiac, neonatal, trauma and emergency medical services traffic all growing, with occupancy up 150 basis points to 73.2% and length of stay still improving. A business with twenty-five service categories can absorb weakness in one and has, for four quarters, while still growing total volume 3.0%.

Bear view: Three causes are now on the table and two of them do not lap. The Medicare inpatient-only list is in year one of a three-year phase-out, is concentrated in orthopaedics today and moves procedures into an outpatient market management itself describes as larger and more competitive. The affordability component has been unsizeable for two consecutive quarters, is reported by the company's own physicians, and shows up at every peer in the same quarter. Outpatient surgery deteriorated sequentially, from (3.4%) to (3.7%), while every other volume metric improved. This is the highest-contribution volume in the business and it is the only line still getting worse.

Our take: We land in the middle and the middle is worse than July. The inpatient-only list is a permanent subtraction with a three-year schedule, which lowers the ceiling on any post-coverage elective recovery no matter how the affordability question resolves. That is a genuine deterioration in the bear case even though the quarter's overall volume improved. The offset we did not give enough weight to in July is composition: the services backfilling the gap are high-acuity, and 150 basis points of occupancy improvement on flat beds is worth real money. Our estimate holds the inpatient elective decline at (4%) to (6%) and no longer assumes a recovery inside the forecast period.

Model Update Needed

Valuation framework. At the October 27 reaction close of $449.96, HCA trades at 15.0 times the midpoint of the upper half of 2026 guidance, 15.8 times our clean 2026 estimate of roughly $28.53, and 15.3 times our 2027 estimate of $29.50. Market value is approximately $97.7B on 217.212 million diluted shares; adding net debt of $49.585B and noncontrolling interests of $3.478B gives an enterprise value near $150.8B, or 9.5 times our derived trailing twelve-month Adjusted EBITDA of $15.861B. The dividend, declared again at $0.78 and payable December 29, yields 0.7% and is not part of the return case.

We build 2027 from a flat Adjusted EBITDA of roughly $15.90B, as management's preliminary frame implies, and carry the depreciation, interest and minority-interest growth this quarter already shows. That produces net income attributable of roughly $6.2B to $6.4B, down modestly on 2026, and EPS between $28 and $31 depending almost entirely on the share count. We center on $29.50 with a 210 million share assumption that requires a new repurchase authorization in the first half. Applying 13.5 to 15.5 times gives a fair value band of approximately $400 to $455, midpoint about $428, roughly 5% below the reaction close.

We shift the multiple range up by half a turn from the 13.0 to 15.0 times applied in July. The justification is specific rather than general: the cost pillar has now confirmed on two consecutive quarters, the second seasonally stacked against it, the volume franchise is delivering at the top of its range, the Medicaid conversion risk is scoped and contained, the exchange book has shown its first sequential improvement, and there is a credible unguided upside channel in 340B for the first time since the Florida approval. What keeps the range below the 15.5 to 17.5 times we used in January is the 2027 ceiling management has now placed on reported earnings, the re-acceleration in professional fees, a permanent new driver inside the elective decline, and the fact that per-share growth depends on a buyback authorization that runs out in roughly ten weeks.

Thesis Scorecard Post-Earnings

Overall: Thesis strengthened on operations and narrowed on valuation. Both bull operating pillars reconfirm, and Bull #1 does so against the seasonality that broke it in January, which retires the last of the Q1 doubts. Bull #3 stays Neutral because the quarter fixed the cash gap and the year has not. On the bear side, the two policy points are now quantified rather than merely active, which is an improvement in knowability without any reduction in size, and the two cost-and-demand points both escalated: professional fees reversed last quarter's improvement and the elective decline acquired a permanent driver. The net is a business we rate more highly than we did in July, operating inside a 2027 envelope management has defined from the top.

Action: Hold maintained. The July downgrade argued that HCA was a well-run business running into a headwind larger than its mitigation capacity, and that the gap would close when the headwind lapped rather than when the mitigation grew. Three months later the mitigation is demonstrably better than we credited, core growth is running at roughly 10%, and the stock is 17.7% higher at $449.96. That combination leaves it at 15.0 times the upper half of 2026 guidance and 15.3 times a 2027 management has pre-described as flat, which is the top of the multiple range we are willing to apply to a policy-capped year. Fair value band $400 to $455, midpoint approximately $428, roughly 5% below the reaction close. We would move to Outperform on either of two specific events: a January guide above "generally consistent with 2026," most plausibly carried by a finalised 340B reallocation and a narrowed exchange assumption built on observed enrollment, or a share price below roughly $400 where the 2027 multiple approaches 13.5 times. We would move to Underperform if the fourth quarter fails to deliver the core growth management says is continuing, or if the repurchase authorization is not replaced. The January call carries both the 2027 guide and the enrollment data that should finally settle the exchange question, and it is the most consequential checkpoint of this coverage.